7 results about "Entry inhibitor" patented technology

The present invention relates to a drug and method for nucleoside (acid) drug therapy of limiting chronic hepatitis B, in particular to the use of an HBV virus entry inhibitor and an optional immunomodulator in the preparation of a drug or kit for nucleoside (acid) drug therapy of limiting or terminating chronic hepatitis B. By using the method provided by the invention, after administering the nucleoside (acid) drug, the HBV virus entry inhibitor and the optional immunomodulator for combined therapy for a certain course of treatment, the drug can be completely stopped, and the patient does not need to continue to accept NAs treatment.

The present invention addresses the problem of providing a virus cell entry inhibitor that inhibits the entry of viruses into cells and makes it possible to prevent viral infections.　A virus cell entry inhibitor that solves the problem of the present invention is characterized by containing at least one selected from an eyebright extract, a kasoori methi extract, a Tartary buckwheat extract, an okra extract, a cinnamon extract, a berberry extract, and a shell ginger extract.

Compounds, compositions, and methods of treatment and prevention of HIV infection are disclosed. The compounds are pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidine JAK inhibitors. Combinations of these JAK inhibitors and additional antiretroviral compounds, such as NRTI, NNRTI, integrase inhibitors, entry inhibitors, protease inhibitors, and the like, are also disclosed. In one embodiment, the combinations include a combination of adenine, cytosine, thymidine, and guanine nucleoside antiviral agents, optionally in further combination with at least one additional antiviral agent that works via a different mechanism than a nucleoside analog. This combination has the potential to eliminate the presence of HIV in an infected patient.

Compounds, compositions, and methods of treatment and prevention of HIV infection are disclosed. The compounds are pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidine JAK inhibitors. Combinations of these JAK inhibitors and additional antiretroviral compounds, such as NRTI, NNRTI, integrase inhibitors, entry inhibitors, protease inhibitors, and the like, are also disclosed. In one embodiment, the combinations include a combination of adenine, cytosine, thymidine, and guanine nucleoside antiviral agents, optionally in further combination with at least one additional antiviral agent that works via a different mechanism than a nucleoside analog. This combination has the potential to eliminate the presence of HIV in an infected patient.

Disclosed herein are broad-spectrum Coronavirus entry inhibitor compounds and methods of use thereof. Methods disclosed herein include inhibiting Coronavirus infection, treating a Coronavirus infection, and treating a subject at risk of contracting a Coronavirus infection. The compounds described herein target entry of Coronaviruses downstream of binding of the viral receptor.

The present application relates to viral entry inhibitors and RNA polymerase inhibitors, pharmaceutical compositions comprising one or more of the same, and combination therapies, as well as methods of making and of using the foregoing in the treatment of certain diseases.

This invention relates to pharmaceuticals and methods for clearing hepatitis B virus (HBV) cccDNA from the livers of hepatitis B virus-infected individuals. Specifically, this invention provides the use of HBV entry inhibitors that inhibit HBV entry into hepatocytes and, optionally, immunomodulatory agents that regulate anti-HBV immunity in the preparation of pharmaceutical combinations or kits used in methods for clearing HBV cccDNA from hepatitis B patients. This invention also provides corresponding pharmaceutical combinations and kits for the above-mentioned uses.